chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient is a 72-year-old male with a history of coronary disease, hypertension, gastroesophageal reflux and who tested positive for Covid 3 days ago after he started developing a cough approximately 3 weeks ago.  Patient states he has been gradually getting sicker and sicker.  He was seen in the emergency room 4 days ago and had a Covid test at that time.  The test came back positive the day before yesterday.  Patient presents to the emergency room today complaining of increasing generalized weakness and shortness of breath even at rest.  Patient admits to subjective fever and chills.  He admits to profound weakness and generalized aches and pains.  Patient did receive the Johnson & Johnson vaccine however never received a booster. Associated Symptoms: back pain, chest pain, chills, cough, diarrhea, dizziness, fatigue, fever, headache, joint pain, nausea, shortness of breath, weakness, wheezing
Information has been received from a 62 year old female consumer with no medical history, drug reactions or allergies who on 31-DEC-2007 was vaccinated with 0.65 ml of ZOSTAVAX. There was no concomitant medication. On 31-DEC-2007 the patient developed redness and swelling at the injection site, and ran low grade fever after receiving the vaccine. There were no lab diagnostic studies performed. The caller also reported that her mother developed a headache after receiving ZOSTAVAX on 31-DEC-2007. The reporter declined to offer any additional information. Additional information has been requested.
This spontaneous case reported by a consumer, describes the occurrence of vaccination complication ("second shot put me down for two weeks") and inappropriate schedule of product administration (more than 35 days between first and second shot) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch/lot# 001C21A and 016B21A) for COVID-19  immunization. No medical history reported. On Mar 30, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On May 10, 2021, patient received second dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On May 10, 2021, patient experienced inappropriate schedule of product administration (more than 35 days between first and second shot). On an unknown date, patient experienced vaccination complication ("second shot put me down for two weeks").  At the time of the report, vaccination complication ("second shot put me down for two weeks") resolved and inappropriate schedule of product administration (more than 35 days between first and second shot) outcome: unknown. No concomitant medication or treatment information reported. The patient received the first and second shot. He stated the second shot put him down for two weeks. The patient was worried about getting the booster shot. Most recent follow-up information incorporated: On Mar 31, 2022: Follow-up received contained no new information.
1st dose vaccine 1/7/21; 2nd dose vaccine 1/28/21; developed low back pain radiating to left leg worse with movements no injuries onset 2/8/21; was seen in same day 2/8/21.
Crying inconsolably 11 x 8 cm area of erythema at injection site - (L) thigh. TYLENOL administered. Advised to apply ice pack.
received booster on 12/30/2022. Exposure to SARS-COV-2 Jan 2-3th 2022. Symptom onset Jan 3 including vaginal bleeding which worsened.  Transvaginal ultrasound 1/26 abnormal with endometrial thickening. Scheduled for a endometrial biopsy 2/3/22
Wenkebach rhythm 1/5/10. H1N1 12/18/09. I had flu like sx 11/5 - 11/15/09. MD said it was H1N1 but did no lab tests.
The pfizer covid-19 vaccine 12+ gray cap was pulled from the fridge instead of the pfizer covid-19 Bivalent 12+ gray cap vial.  This was not noticed until pharmacist on duty was reporting waste report into EPRN and the lot# and vial information did not match the Pfizer Bivalent vaccine.  Patient was called and left a voicemail. They could get the new booster in 2 months time.
Feeling  very sick, fatigue. feeling like low blood pressure. now the symptoms are showing after 6weeks again the same fatigue, tiredness.
Few days after injection, felt nerve pain down left (L) arm. This continued for 2 weeks before resolution.
--Patient (and patient's husband) report that patient was  given 2 doses of Pfizer Covid 19 vaccine 6 days apart at the Health Department. --First dose: 2/3/21.  Second dose: 2/9/21 --Patient was admitted to hospital on the evening of 2/9/21 with weakness, shortness of breath "feeling winded". --Patient reports feeling bad and coughing 2-3 days before being vaccinated and does NOT believe her admission to the hospital was associated with the vaccine.   --County health department has been notified.
Anaphylaxis: hives all over her body, lightheadedness, throat closing. Hypotension about 2 hours after the  moderna was administered.. She received 2 doses of epipen before paramedics took her to the ER.
Information has been received from a physician concerning a 15 year old female patient who on 24-JUN-2010 was vaccinated with the third dose of GARDASIL intramuscularly (lot number 662304/1013Y). Concomitant therapy included MENACTRA. The physician stated that on 24-JUN-2010 the patient was using GARDASIL and experienced syncope. The patient did not seek medical attention. At the time of this report, the patient's outcome was unknown. Additional information has been requested.
Daughter of client reports that five days post vaccination, the client developed fever (103 deg. F.), constant diarrhea, body aches so severe she could not stand for anything; restlessness. Daughter states symptoms continued to worsen requirin ER visit on 03/26/2002 upon which client was admitted to hospital. Annual follow up states it is unknown if pt recovered.
Pt recvd HIB-TITER on 18DEC90; On 23APR91 pt was inadvertently administered HIB Conjugate vax instead of booster dose of HIB Polysaccharide; @ time of report, there had been no noted rxn;
This spontaneous report was received from a physician, via company representatives, and refers to a patient of unknown age and gender. Information about the patient's pertinent medical history, drug reactions or allergies and concomitant medications was not reported. On 09-MAR-2015, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 -10PK-0.5ml SD-PFS LLok w Tip, which had the lot # K010465, with expiration date 23-MAR-2016 (dosage number and route of administration were not reported). No adverse effects were reported and no product quality complaint was involved. On unspecified dates, the vaccine experienced temperature excursions of 8 hours. The lowest recorded temperature was 33 F (0.555555556 Celsius degree). The vaccine status was reported as "in excursion". The vaccine storage criteria and the storage type were reported as "Refrigerator(R)". This is one of the several reports received from the same reporter. Additional information has been requested.
Patient received her vaccine and waited with her mother for the 15 minutes.  They were about to leave and the mother called me over.  Patient was nauseous, had a headache, had blotchiness on her chest and  stated she was having some heart palpitations.  She denied the call to 911.  With the blotchiness, 10 ml of liquid diphenhydramine was administered.  Water was given but never used.  I sat with her and asked for frequent updates.  She denied the 911 call a few more times.  At 4:32 pm she stated she wanted to leave so she could lay down in bed.  Her mother escorted her out.
She had lower pain in her legs, back.  Hurting and in a lot of pain.
INADVERTANT TEMPERATURE EXCURSION, VACCINE WAS STORED IN FREEZER TEMPERATURES (-50° C TO -15° C) BEYOND THE ALLOWABLE TWO WEEK EXCURSION THEN ADMINISTERED TO PATIENT. NO PATIENT ISSUES REPORTED FROM VACCINE.
This spontaneous report as received from a certified medical assistant, refers to multiple unspecified patients of unknown age and gender. No medical history and concurrent conditions were reported for the patients. On an unspecified date in 2015, starting from and after 03-AUG-2015, the unspecified patients were vaccinated with improperly stored doses of VAQTA lot # K012456, expiration date 28-APR-2017 nad lot # L002717, expiration date 02-JUN-2017 (dose, frequency and route were not reported). No concomitant medications were reported. No adverse effects were reported. No product quality complaint was involved. This is one of several reports from the same source. Additional information has been requested.
A 21-year-old male patient in the 15-minute observation area turns pale, cold and sweaty and tells his father that he feels bad. Patient reports dizziness and blurred vision. The patient was taken to the Paramedic area where he was evaluated and placed in an elevated leg anti-shock position. Breaths 16, Sat. 99%, B/P 90/60, Pulse 50, At 1:58 pm Pt has normal color, no sweating no longer dizzy and no blurry vision. Pt. Re-valued B/P 110/70 pulse 64, sat. 100%, Res 16 is consulted by Doctor, who discharges him.
fatigue; general malise; Chills; body ache; headache; slept appx. 19 out of 24 hours per day; This is a spontaneous report from a contactable consumer(patient). A 49-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Batch/Lot Number: Not Reported, Expiry Date: Not Reported), via an unspecified route of administration, administered in Arm Left on 17Feb2021 (at the age of 49-year-old) at 17:15 as dose 1, single for COVID-19 immunisation. The patient medical history was not reported. Concomitant medication(s) included clonazepam (CLONAZEPAM) taken for an unspecified indication, start and stop date were not reported; allopurinol (ALLOPURINOL) taken for an unspecified indication, start and stop date were not reported; sertraline hydrochloride (ZOLOFT) taken for an unspecified indication, start and stop date were not reported. The patient did not receive any other vaccine in four weeks. It was unknown if the patient was diagnosed with covid prior vaccination. The patient was not tested for covid post vaccination. On 17Feb2021 at 18:30, the patient experienced fatigue, general malaise. On an unspecified date in feb2021 that is on days two and three, the patient experienced chills, body aches, headache, slept appx. 19 out of 24 hours per day. On day four, there was a slight improvement, slept 16 out of 24 hours. On day five, the adverse event improved, but still feeling about 70% well. The patient did not receive any treatment for the reported event. Outcome of the events was recovered with sequelae.   No follow-up attempts are needed; information about lot/batch number cannot be obtained
Pt developed headache 2-3 hrs after immunization. Low grade fever, pale, and upset stomach on 02/03/2002-02/04/2002.
area of superficial erythema, inc warmth distal to rt deltoid IM inj site;
Rash on both arms from elbow to wrist. Patient did not report the incident to the pharmacy until 2 weeks after injection.
Incorrect Dose Moderna booster dose administered was 0.5 milliliters. Booster dose should have been 0.25 milliliters.
In evening after shot, right hand numb, then chest and right arm severe pain to move, right side of face numb, trouble breathing.
Can feel where they injection was; Red, itchy spot; Headache; Nausea; Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE DISCOMFORT (Can feel where they injection was), PRURITUS (Red, itchy spot), DIARRHOEA (Diarrhea), HEADACHE (Headache) and NAUSEA (Nausea) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event .     On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced DIARRHOEA (Diarrhea) and NAUSEA (Nausea). On an unknown date, the patient experienced INJECTION SITE DISCOMFORT (Can feel where they injection was), PRURITUS (Red, itchy spot) and HEADACHE (Headache). At the time of the report, INJECTION SITE DISCOMFORT (Can feel where they injection was), PRURITUS (Red, itchy spot), DIARRHOEA (Diarrhea), HEADACHE (Headache) and NAUSEA (Nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided No treatment information provided
PT HAD BEEN MISTAKEN AND ASKED FOR A FLUZONE HD ON 10.26.2021 BUT DID NOT REMEMBER THAT SHE ALREADY HAD THE SAME VACCINE ADMINISTERED ON 09/21/2021. NO ADVERSE REACTIONS/EFFECTS REPORTED BY PATIENT. MD CONTACTED AND NOTED IN PATIENT CHART.
Swelling, weakness, wheezing. Area where vaccine given red, hot. Advised ice, TYLENOL. If symptoms worse-ED. Per pt. also taking BENADRYL.
Patient had a 25 minute generalized tonic-clonic seizure in the setting of a fever. Seizure was broken with ATIVAN and fosphenytoin, and he was intubated and extubated.
headache; body aches; she has chills; she can´t get up; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache), PAIN (body aches), CHILLS (she has chills) and FATIGUE (she can´t get up) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HEADACHE (headache), PAIN (body aches), CHILLS (she has chills) and FATIGUE (she can´t get up). At the time of the report, HEADACHE (headache), PAIN (body aches), CHILLS (she has chills) and FATIGUE (she can´t get up) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information and concomitant medications were reported.
This spontaneous report was received from a 60 year old female consumer, reporting on herself with hypertension. On 08-SEP-2014, the patient was vaccinated with a dose of ZOSTAVAX (dose and frequency reported as 1 ZOSTAVAX injection (dose number, lot number, expiration date and route were not reported) for prevention of shingles. Concomitant therapies included lisinopril (manufacturer unknown). Patient reported that on 08-SEP-2014, she experienced redness at the injection site after being administered ZOSTAVAX vaccine and there was a small lump. The patient also felt heat around the injection site area. On 09-SEP-2014 (reported as next day), the redness that was only surrounding the injection site, "grew" to about four to five diameters. The same day; the redness went from the injection site, all the way down to her elbow following the under muscle of her arm in a streak like pattern. Patient also experienced flu-like symptoms that included high fever, shaking, and soreness in her joints. At the time of the report the outcome of the event were unknown. Patient received treatment with ibuprofen, BENADRYL and BENADRYL cream. Patient did not seek for medical attention for the adverse events. Additional information has been requested.
Later that night after patient received shingrix, she couldn't feel her face and started drooling. She woke up the next morning and couldn't feel anything. She ended up in the hospital the following day.  She also reports that she ended up with shingles, but she's not sure if this was from vaccine or if it was already in her body. She has missed 2 months of work.  2 months later she is slightly better but not 100%.
The pt developed cellulitis. Prescribed Cefzil 250 mg for 7 days/
6/5/00 Patient noted to have multiple hive-like eruptions on her back which were red, slightly raised and diffuse but not itchy. Prior to this eruption, patient had been outdoors weeding and noticed a few insect bites on knees and back of neck. 6/11/00 Patient felt shaky with abnormal stool. She was seen in the ER and treated with IV fluids for dehydration. 6/13/00 Patient was seen by family physician still shaky and unsteady with frequent stools. Patient had probable intestinal virus and was improved by 6/24/00. 6/26/00 Patient became lightheaded, tired, woozy and had difficulty focusing. She had a 3 to 4 week period of transient lightheadedness, depth perception difficulty, chills and fatigue. 8/10/00 Patient continued with fatigue and lightheadedness. 8/31/00 Patient had episode of horizontal wavy lines in vision. She was seen by an infectious disease physician with probable Lyme. She was given an RX for doxycycline, 100mg daily x 21. 9/18/00 Patient experienced wavy lines in vision and tumbling sensation. 9/19/00 Patient seen by infectious disease physician and referred to neurology, possible Meniere's Disease, possible vestibular problem. Patient given second series of doxycycline. 10/00 Patient seen by neurology and ENT. Infectious disease physician states possible mono. 11/6/00 Patient sought second opinion. 12/3/00 Patient received oral antibiotics with some improvement.
pt recv vax 5SEP95; employee noted soreness @ inj site later same day; next day noted joint stiffness; 3rd day significant body aches, joint pain, h/a; also c/o pain & swelling @ inj site; advised to take ibuprofen;
Dr. called today and was concerned because patient had neuritis in her chest and shoulder. She felt it was some nerve distribution from the influenza vaccine. Unable to put shirt on x 1 week. Dr said she does not have shingles she called because she was concerned about the brand.
Tickle/slight cough lasted < 1 minute.  Patient anxious. Placed supine BP 159/63  HR 100 Sat 97%     Observed. Symptoms resolved
Severe central nervous system hypersensitivity; Severe central nervous system hypersensitivity; inappropriate sinus tachycardia; severe GI trauma; Jarisch-Herxheimer reaction; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 27Mar2021 12:15 (Lot number: ER8727) at the age of 69 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "IGG allergies to many foods" (unspecified if ongoing), notes: Known allergies: IGG allergies to many foods. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Product=COVID 19, brand=Pfizer, lot number=EN6205, administration date=06Mar2021, administration time=12:15 PM, dose number=1, vaccine location=Left arm), administration date: 06Mar2021, when the patient was 69 years old, for Covid-19 Immunisation. The following information was reported: HYPERSENSITIVITY (non-serious), NERVOUS SYSTEM DISORDER (non-serious) all with onset May2021, outcome "not recovered" and all described as "Severe central nervous system hypersensitivity"; SINUS TACHYCARDIA (non-serious) with onset May2021, outcome "not recovered", described as "inappropriate sinus tachycardia"; GASTROINTESTINAL DISORDER (non-serious) with onset May2021, outcome "not recovered", described as "severe GI trauma"; JARISCH-HERXHEIMER REACTION (non-serious) with onset May2021, outcome "not recovered", described as "Jarisch-Herxheimer reaction". The events "severe central nervous system hypersensitivity", "severe central nervous system hypersensitivity", "inappropriate sinus tachycardia", "severe gi trauma" and "jarisch-herxheimer reaction" were evaluated at the physician office visit. Therapeutic measures were not taken as a result of hypersensitivity, nervous system disorder, sinus tachycardia, gastrointestinal disorder, jarisch-herxheimer reaction.  Additional information: Prior vaccination within 4 weeks was reported as none. COVID prior vaccination and COVID tested post vaccination was reported as none. Severe central nervous system hypersensitivity, inappropriate sinus tachycardia and severe GI trauma. If the research on this link: (Link).aspx proves valid it would appear that the vaccine reprogrammed my immune system to kill Candida fungus and the symptoms are due to a Jarisch-Herxheimer reaction resulting from killing the fungus to fast.  Follow-up attempts are completed. No further information is expected.
This case was reported by a other health professional via sales rep and described the occurrence of suspected vaccination failure in a female patient who received FLUARIX QUADRIVALENT for prophylaxis. On an unknown date, the patient received FLUARIX QUADRIVALENT at an unknown dose. On an unknown date, 21 days after receiving FLUARIX QUADRIVALENT, the patient experienced vaccination failure (serious criteria GSK medically significant) and influenza. On an unknown date, the outcome of the vaccination failure and influenza were unknown. It was unknown if the reporter considered the vaccination failure and influenza to be related to FLUARIX QUADRIVALENT. Additional information received as follows: The case was reported by the office manager. The patient (worker in this office) took Fluarix QIV and 2 to 3 weeks later got the flu. This case was considered as a suspected vaccination failure case as the lab test confirmation for influenza were unknown. The reporter agreed to follow up from GlaxoSmithKline. This is 1 of the 3 linked cases reported by the same reporter.
This spontaneous report was received from a registered nurse and refers to a 16 year old male patient. The patient's concurrent conditions, medical history and concomitant therapies were not reported. The stock of vaccine was received on 11-OCT-2016. On 17-JAN-2017, the patient was vaccinated with an improperly stored dose of PROQUAD, lot # M023931 with expiration date of 09-NOV-2017 (dose, route and frequency were not reported) for prophylaxis. It was stated that the vaccine underwent a temperature excursion of 6 degrees Fahrenheit to 14 degrees Fahrenheit for 37 days. It was reported that there was no need to repeat vaccine. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1705USA013888.
Pt was given vaccination ~ 5pm on Tuesday and be the next day (Wed) started experiencing dizziness - She feels her dizziness was so severe that she passed out briefly, fell, banged her head & then woke up. She had a minor cut on her head but her MD checked her out a found no other complication on 1/21/20.
Experienced right foot pain then next day 04/03/2015 experienced left foot pain.  Both feet painful to walk on 04/03/15, 04/04/2015, 04/05/2015, and 04/06/2015. On 04/06/2015 pain in both feet is less severe.
Injection site soreness and throbbing pain all day long in upper left arm. Throbbing pain has continued for the past month.
Received Pneumovax 9/17/07 Developed urticaria on arm near and surrounding injection on 9/19.
Covid vaccine given through outside source  J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/4/2022 ASPIRATION PNEUMONIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/4/2022 ANEMIA
pt hosp on 3/18 w/respiratory syncytial virus infect & while in hosp devel diarrhea; stool specimen pos for rotavirus antigens; as of 3/23 pt exp up to 7 loose stools per day
Pt called Sunday morning stating that her left eye and the side of her face had significant swelling and she believes it was an ADE from a pfizer bivalent booster given on Friday. She's not entirely sure it's from the shot, but it's on the same side of the body as her vaccine. I advised her to take 50 mg diphenhydramine and I called her a couple hours later to check in. Pt thought the swelling went down a bit. If anything changes for the worst, I told her to go to urgent care or call her pcp. Pt is not very worried and mostly just wanted to report the ADE. At her request, I gave her the info for VAERS reporting so she can report the ADE.